CA3189248A1 - Functionalized peptides as antiviral agents - Google Patents

Functionalized peptides as antiviral agents

Info

Publication number
CA3189248A1
CA3189248A1 CA3189248A CA3189248A CA3189248A1 CA 3189248 A1 CA3189248 A1 CA 3189248A1 CA 3189248 A CA3189248 A CA 3189248A CA 3189248 A CA3189248 A CA 3189248A CA 3189248 A1 CA3189248 A1 CA 3189248A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
alkyl
cycloalkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3189248A
Other languages
English (en)
French (fr)
Inventor
Joseph D. Panarese
Dexter DAVIS
Nathaniel Thomas Kenton
Samuel Bartlett
Sean M. Rafferty
Yat Sun Or
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enanta Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3189248A1 publication Critical patent/CA3189248A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3189248A 2020-08-13 2021-08-12 Functionalized peptides as antiviral agents Pending CA3189248A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063065283P 2020-08-13 2020-08-13
US63/065,283 2020-08-13
PCT/US2021/045632 WO2022036018A1 (en) 2020-08-13 2021-08-12 Functionalized peptides as antiviral agents

Publications (1)

Publication Number Publication Date
CA3189248A1 true CA3189248A1 (en) 2022-02-17

Family

ID=80223910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3189248A Pending CA3189248A1 (en) 2020-08-13 2021-08-12 Functionalized peptides as antiviral agents

Country Status (12)

Country Link
US (1) US20220048944A1 (de)
EP (1) EP4196117A1 (de)
JP (1) JP2023537402A (de)
KR (1) KR20230070207A (de)
CN (1) CN116547294A (de)
AU (1) AU2021324764A1 (de)
BR (1) BR112023002573A2 (de)
CA (1) CA3189248A1 (de)
CO (1) CO2023002852A2 (de)
IL (1) IL300589A (de)
MX (1) MX2023001756A (de)
WO (1) WO2022036018A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021383832A1 (en) 2020-11-23 2023-06-22 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
AU2022283816A1 (en) 2021-06-02 2024-01-04 ACEA Therapeutics, Inc. Protease inhibitors as antivirals
US20230033285A1 (en) * 2021-06-16 2023-02-02 The Scripps Research Institute Protease Inhibitors for Treatment of Coronavirus Infections
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
WO2023086400A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
US12006291B2 (en) 2022-01-11 2024-06-11 Enanta Pharmaceuticals, Inc. Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2850003C (en) * 2011-09-27 2020-01-07 Kansas State University Research Foundation Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses
US11124497B1 (en) * 2020-04-17 2021-09-21 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof

Also Published As

Publication number Publication date
WO2022036018A1 (en) 2022-02-17
IL300589A (en) 2023-04-01
EP4196117A1 (de) 2023-06-21
CO2023002852A2 (es) 2023-06-09
KR20230070207A (ko) 2023-05-22
JP2023537402A (ja) 2023-08-31
MX2023001756A (es) 2023-05-04
AU2021324764A1 (en) 2023-03-16
BR112023002573A2 (pt) 2023-03-14
US20220048944A1 (en) 2022-02-17
CN116547294A (zh) 2023-08-04

Similar Documents

Publication Publication Date Title
WO2022020242A1 (en) Functionalized peptides as antiviral agents
CA3189248A1 (en) Functionalized peptides as antiviral agents
US11325916B1 (en) Spiropyrrolidine derived antiviral agents
US11976084B2 (en) Spiropyrrolidine derived antiviral agents
CA3173333A1 (en) Novel spiropyrrolidine derived antiviral agents
US11858945B2 (en) Alkyne-containing antiviral agents
US11993600B2 (en) Saturated spirocyclics as antiviral agents
AU2021383832A9 (en) Novel spiropyrrolidine derived antiviral agents
US20230103494A1 (en) Novel spiropyrrolidine derived antiviral agents
WO2023091561A1 (en) Novel spiropyrrolidine derived antiviral agents
WO2023086352A1 (en) Novel spiropyrrolidine derived antiviral agents
US20230122228A1 (en) Novel spiropyrrolidine derived antiviral agents
WO2023196307A1 (en) Novel spiropyrrolidine derived antiviral agents
WO2023009187A1 (en) Novel spiropyrrolidine derived antiviral agents
WO2023107417A1 (en) Heterocyclic antiviral agents
CA3173702A1 (en) Novel spiropyrrolidine derived antiviral agents